← Back to Search

Other

A Study to Assess the Adverse Events and How Oral ABBV-552 Capsules Moves Through the Body of Healthy Adult Japanese and Han Chinese Participants

Phase 1
Waitlist Available
Research Sponsored by AbbVie
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to approximately 45 days
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a new drug called ABBV-552, which might help treat Alzheimer's disease. It involves healthy Japanese and Han Chinese adults to see how their bodies handle the drug. Researchers will observe how the drug moves through their bodies and check for any side effects.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to approximately 45 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to approximately 45 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
AUC From Time Zero to Infinite Time (AUCinf) of ABBV-552
AUC of ABBV-552 (Arm 1)
Apparent Oral Clearance (CL/F) of ABBV-552
+8 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Arm 2: Healthy Han Chinese ParticipantsExperimental Treatment1 Intervention
Participants will receive ABBV-552 once a week for 7 Days.
Group II: Arm 1: Healthy Japanese ParticipantsExperimental Treatment1 Intervention
Participants will receive ABBV-552 once a week for 21 Days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ABBV-552
2023
Completed Phase 2
~290

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AbbVieLead Sponsor
1,035 Previous Clinical Trials
523,026 Total Patients Enrolled
ABBVIE INC.Study DirectorAbbVie
456 Previous Clinical Trials
163,675 Total Patients Enrolled
~6 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top